Myeloid Therapeutics Strengthens Senior Team to Support the Expansion of its Manufacturing Capabilities CAMBRIDGE, Mass, August 23, 2022 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company harnessing the power of myeloid and innate biology to engineer novel therapies that elicit a broad immune response for cancer and autoimmune diseases, today announced that it […]
Myeloid Therapeutics Strengthens its Board of Directors with Appointments of Stanley Frankel, M.D., FACP and Brett Kaplan, M.D. CAMBRIDGE, Mass, June 30, 2022 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company harnessing the power of myeloid and innate biology to engineer novel therapies that elicit a broad immune response for cancer and autoimmune […]
CAMBRIDGE, Mass, May 24, 2022 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today announced that it will participate in the following investor conferences during June 2022: Wells Fargo Private Biotech Symposium, taking place virtually on June 1, 2022 Healthcare Conference, taking place in New […]
Myeloid Therapeutics Enters Into Agreement with Acuitas Therapeutics for Lipid Nanoparticle System..
Myeloid Therapeutics Enters Into Agreement with Acuitas Therapeutics for Lipid Nanoparticle (LNP) System, Enabling the First-Ever Delivery of mRNA-Encoded CARs Directly to Humans – Myeloid’s monocyte-specific CAR technology combined with Acuitas’ industry-leading LNP portfolio will accelerate in vivo cell programming for cancer patients – – This strategic step complements Myeloid’s existing pipeline and illustrates its […]
Myeloid Therapeutics Doses First Patient with MT-101 in the IMAGINE Phase 1/2 Clinical Study, Marking the First-ever Dosing of an mRNA Engineered CAR Monocyte to Humans -Myeloid dosed MT-101 in a patient with refractory PTCL within 18 months, illustrating the potential of mRNA therapies to help patients sooner and to accelerate Myeloid’s portfolio- -Myeloid achieved […]
CAMBRIDGE, Mass, April 19, 2022 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today announced that it will participate in one-on-one and small group meetings with investors at the Morgan Stanley Private Company Biotech Corporate Access Day.The conference is being held in a virtual format […]
Myeloid Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Ability of its ATAK™
Late-Breaking Data at AACR 2022: Ability of its ATAK™ Receptors and in vivo Delivery of mRNA to Attack Cancer by Immune Reprogramming CAMBRIDGE, Mass, April 10, 2022 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today presented new late-breaking data at the American Association for […]
to Develop and Accelerate Next-Generation RNA-based Gene-Editing Technology, RetroT™ — Myeloid’s novel RetroT™ technology may enable targeted insertion of gene-sized DNA sequences into the genome, creating new opportunities for programmable gene editing — Myeloid received a $45 million upfront payment from Prime, and is eligible for significant future milestone payments — CAMBRIDGE, Mass, March 31, […]
CAMBRIDGE, Mass., March 10, 2022 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today announced that company management will present a corporate overview at Oppenheimer’s 32nd Annual Healthcare Conference and will participate in one-on-one meetings with investors. The conference is being held in a […]
Late-Breaking Presentations on mRNA in-vivo Delivery and ATAK™ CAR Receptors CAMBRIDGE, Mass., March 9, 2022 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today announced that it will present two late-breaking posters at the American Association for Cancer Research (AACR) Annual Meeting taking place […]